The POUR (Postoperative Urinary Retention) Study

PHASE3CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

September 3, 2024

Study Completion Date

September 3, 2024

Conditions
Postoperative Urinary Retention
Interventions
DRUG

Sugammadex

The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.

Trial Locations (1)

28204

Carolinas Medical Center, Charlotte

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER